ERBB2 and cancer: The non‐immune mechanism results from the binding of antibody fragment antigen‐binding (Fab) domains to HER2 receptors, leading to the anti‐proliferative effects of cancer cells by perturbing HER2‐signalling (Slamon et al., 2001).